Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (111-120 of 367) with videos related to

Pageof 37
Sort By:
Journal for Immunotherapy of Cancer|July 23, 2025
Response to: Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by ZhuMichiel M Smeenk, Vincent van der Noort, Jeroen J M A Hendrikx, et al.
BMC Cancer|July 5, 2011
The use of erlotinib in daily practice: a study on adherence and patients' experiencesLonneke Timmers, Christel C L M Boons, Dirk Mangnus, et al.
Journal for Immunotherapy of Cancer|November 28, 2025
Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better?Daphne van der Geest, Alex van Vliet, Daniel S Peeper, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 17, 2012
An 82-year-old woman with small-cell lung cancer: relapse after 9 years or a new primary?Martijn R Groenendijk, Erik Thunnissen, Bauke Ylstra, et al.
EJNMMI Research|June 10, 2015
Pilot study of (89)Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancerIdris Bahce, Marc C Huisman, Eline E Verwer, et al.
Proteomics. Clinical Applications|April 5, 2016
Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancerMaria Rovithi, Joline S W Lind, Thang V Pham, et al.
British Journal of Cancer|August 1, 2018
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatmentAdrianus J de Langen, M Jebbink, Sayed M S Hashemi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2015
Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?Julien P L Vincenten, Egbert F Smit, Katrien Grünberg, et al.
Molecular Imaging and Biology|July 2, 2013
Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancerVirginie Frings, Adrianus J de Langen, Maqsood Yaqub, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 22, 2013
KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive valueWouter W Mellema, Anne-Marie C Dingemans, Erik Thunnissen, et al.
Pageof 37

Showing results (111-120 of 367) with videos related to

Sort By:
Pageof 37
Journal for Immunotherapy of Cancer|July 23, 2025
Response to: Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by ZhuMichiel M Smeenk, Vincent van der Noort, Jeroen J M A Hendrikx, et al.
BMC Cancer|July 5, 2011
The use of erlotinib in daily practice: a study on adherence and patients' experiencesLonneke Timmers, Christel C L M Boons, Dirk Mangnus, et al.
Journal for Immunotherapy of Cancer|November 28, 2025
Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better?Daphne van der Geest, Alex van Vliet, Daniel S Peeper, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 17, 2012
An 82-year-old woman with small-cell lung cancer: relapse after 9 years or a new primary?Martijn R Groenendijk, Erik Thunnissen, Bauke Ylstra, et al.
EJNMMI Research|June 10, 2015
Pilot study of (89)Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancerIdris Bahce, Marc C Huisman, Eline E Verwer, et al.
Proteomics. Clinical Applications|April 5, 2016
Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancerMaria Rovithi, Joline S W Lind, Thang V Pham, et al.
British Journal of Cancer|August 1, 2018
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatmentAdrianus J de Langen, M Jebbink, Sayed M S Hashemi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2015
Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?Julien P L Vincenten, Egbert F Smit, Katrien Grünberg, et al.
Molecular Imaging and Biology|July 2, 2013
Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancerVirginie Frings, Adrianus J de Langen, Maqsood Yaqub, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 22, 2013
KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive valueWouter W Mellema, Anne-Marie C Dingemans, Erik Thunnissen, et al.
Pageof 37